

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BaWang International (Group) Holding Limited

霸王國際（集團）控股有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 01338)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND MEMBER OF AUDIT AND RISK MANAGEMENT COMMITTEE

The board of directors (the “**Board**”) of BaWang International (Group) Holding Limited (the “**Company**”) is pleased to announce that Dr. Wang Qi (“**Dr. Wang**”) has been appointed as an independent non-executive director and a member of the audit and risk management committee of the Company with effect from 17 April 2018.

Dr. Wang Qi, aged 38, is currently the vice director of the Dongguan Institute of Opto-electronics, Peking University. Prior to that, from 2010 to 2012, he was a research associate in the Department of Electronic and Electrical Engineering of the University of Sheffield in the United Kingdom, and also worked at Seren Photonics Ltd, a company in the United Kingdom which focuses on the development and manufacturing of semi-polar and non-polar Gallium Nitride templates. From 2012 to 2014, he was a postdoctoral research fellow in the Department of Electrical and Computer Engineering of McGill University in Canada.

Dr. Wang is a member of the Dongguan committee of the Jiusan Society* (九三學社東莞市委員會), the chairman of the Songshan Lake branch of the Dongguan committee of the Jiusan Society* (九三學社東莞市委員會松山湖支社), a vice chairman of the technological innovation promotion committee of the Dongguan Committee of the Jiusan Society* (九三學社東莞市委員會促進科技創新專門工作委員會), an entrepreneurship mentor of the Dongguan Business Incubation Association* (東莞市科技企業孵化協會) and a member of the Dongguan Songshan Lake High-tech Industry Development Zone Science and Technology Association* (東莞松山湖高新技術產業開發區科學技術協會). He is also the legal representative and an executive director of the Dongguan Yanyuan Technological Assets Management Company Limited* (東莞燕園科技產業管理有限公司). He was recognised as a special professional of Dongguan City (3rd class distinctive talent) by the Office for the Administration of Talent Affairs of Dongguan City in 2017.

Dr. Wang obtained a bachelor’s degree in physics (magnetism) from Lanzhou University in 2001. He studied at the Department of Physics of Peking University from 2002 to 2008. He obtained a Doctor of Philosophy in the Faculty of Engineering Department of Electronic and Electrical Engineering from the University of Sheffield in the United Kingdom in 2010.

Save as disclosed above, Dr. Wang (i) does not hold any other positions within the Company, (ii) has no other major appointments and professional qualifications, and (iii) did not hold any directorship in the last three years in public companies, the securities of which are listed on any securities market in Hong Kong or overseas. As far as the Board is aware, Dr. Wang does not have any relationship with any director, senior management or substantial or controlling shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) of the Company. As at the date of this announcement, Dr. Wang does not have any interests in the securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance. Dr. Wang has confirmed that he meets the independence criteria as set out in Rule 3.13 of the Listing Rules.

Pursuant to a letter of appointment for a fixed term of three years signed between Dr. Wang and the Company, Dr. Wang is entitled to a director’s fee of HK\$200,000 per annum which was determined by the Board based on the recommendation of the Remuneration Committee of the Company with reference to his experience, duties, responsibilities and the prevailing market conditions. Dr. Wang will hold office until the next following annual general meeting of the Company and shall then be eligible for re-election pursuant to the Company’s articles of association.

Save as disclosed above, Dr. Wang and the Company are not aware of any other matters that need to be brought to the attention of the shareholders of the Company and there is no information that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules in connection with the appointment of Dr. Wang.

Following the appointment of Dr. Wang as an independent non-executive director and a member of the audit and risk management committee, the Company has re-complied with the requirements under Rules 3.10(1) and 3.21 of the Listing Rules.

Taking this opportunity, the Board would like to express its warmest welcome to Dr. Wang for joining the Board.

By order of the Board
BaWang International (Group) Holding Limited
CHEN Qiyuan
Chairman

Hong Kong, 17 April 2018

As at the date of this announcement, the Board comprises three executive Directors, namely Mr. CHEN Qiyuan, Mr. CHEN Zheng He and Mr. WONG Sin Yung, and three independent non-executive Directors, namely Dr. NGAI Wai Fung, Mr. CHEUNG Kin Wing and Dr. WANG Qi.

**For identification purpose only.*